Logo image of SUMR

Summer Infant Inc (SUMR) Stock Fundamental Analysis

NASDAQ:SUMR - US8656463010 - Common Stock

11.99
+0.01 (+0.08%)
Last: 6/21/2022, 8:00:02 PM
Fundamental Rating

0

Overall SUMR gets a fundamental rating of 0 out of 10. We evaluated SUMR against 36 industry peers in the Personal Care Products industry. SUMR may be in some trouble as it scores bad on both profitability and health. SUMR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SUMR has reported negative net income.
SUMR Yearly Net Income VS EBIT VS OCF VS FCFSUMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 5M -5M 10M 15M

1.2 Ratios

Industry RankSector Rank
ROA -8.62%
ROE 6.15%
ROIC -11.23%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SUMR Yearly ROA, ROE, ROICSUMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -20 -40 -60 -80 -100

1.3 Margins

Industry RankSector Rank
OM -4.56%
PM (TTM) -4.99%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SUMR Yearly Profit, Operating, Gross MarginsSUMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 10 20 30

More info and screens

1

2. Health

2.1 Basic Checks

SUMR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for SUMR has been increased compared to 1 year ago.
The debt/assets ratio for SUMR is higher compared to a year ago.
SUMR Yearly Shares OutstandingSUMR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 500K 1M 1.5M 2M
SUMR Yearly Total Debt VS Total AssetsSUMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

SUMR has an Altman-Z score of 0.67. This is a bad value and indicates that SUMR is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -27.58 indicates that SUMR is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -27.58
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACC-0.95
WACC11.83%
SUMR Yearly LT Debt VS Equity VS FCFSUMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M 20M 30M 40M

2.3 Liquidity

SUMR has a Current Ratio of 1.46. This is a normal value and indicates that SUMR is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 0.86 indicates that SUMR may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 0.86
SUMR Yearly Current Assets VS Current LiabilitesSUMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for SUMR have decreased strongly by -2109.09% in the last year.
The Revenue has decreased by -6.16% in the past year.
The Revenue has been decreasing by -5.86% on average over the past years.
EPS 1Y (TTM)-2109.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.5%
Revenue 1Y (TTM)-6.16%
Revenue growth 3Y-6.12%
Revenue growth 5Y-5.86%
Sales Q2Q%-5.03%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-3.74%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SUMR Yearly Revenue VS EstimatesSUMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M
SUMR Yearly EPS VS EstimatesSUMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 0 0.5 1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SUMR. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SUMR Price Earnings VS Forward Price EarningsSUMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.9
SUMR Per share dataSUMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SUMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Summer Infant Inc

NASDAQ:SUMR (6/21/2022, 8:00:02 PM)

11.99

+0.01 (+0.08%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)05-17 2022-05-17/bmo
Earnings (Next)08-15 2022-08-15
Inst Owners0%
Inst Owner Change0%
Ins Owners80.03%
Ins Owner Change0%
Market Cap26.02M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.18
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -14.9
EPS(TTM)-3.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS65.36
BVpS-0.59
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE 6.15%
ROCE N/A
ROIC -11.23%
ROICexc N/A
ROICexgc -14.94%
OM -4.56%
PM (TTM) -4.99%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover1.73
Health
Industry RankSector Rank
Debt/Equity -27.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 0.86
Altman-Z 0.67
F-Score1
WACC11.83%
ROIC/WACC-0.95
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2109.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.16%
Revenue growth 3Y-6.12%
Revenue growth 5Y-5.86%
Sales Q2Q%-5.03%
Revenue Next Year-3.74%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A